AlphAIAlphAI — Financial news for AI agents
finanznachrichten.de$EVAX

Evaxion: New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

Original reporting
finanznachrichten.de
Published Nov 6, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The disclosed 75% objective response rate and strong T‑cell activation suggest a high probability of advancing to later‑stage trials, which could materially affect valuation.

02

Market read

First‑time release of robust phase 2 data is a primary catalyst for EVAX and may influence peer biotech valuations.

03

What to watch

Regulatory timeline, manufacturing scalability, and competition from other personalized vaccine platforms.

Relevance 8/10Novelty 8/10Timing: today

Background

Evaxion A/S (NASDAQ: EVAX) presented new phase 2 biomarker data for its personalized cancer vaccine EVX-01 at the SITC 2026 meeting.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Phase 2 trial of EVX-01 in advanced melanoma shows 75% objective response rate and strong neoantigen-specific T‑cell responses.

Expected impact

potential upside as market prices in the robust immune response data

Evidence & confidence

Phase 2 biomarker results are first‑time disclosure and indicate high efficacy, a material catalyst for a biotech.

Market effects

Sector

May boost sentiment for AI‑driven immunotherapy sector and related biotech peers.

Regional

Limited to US and European biotech markets.

Global

Modest; primarily affects niche biotech investors.

Counterpoint

What could challenge this read

Data could be over‑hyped; long‑term efficacy and commercial viability remain uncertain.

Key entities

  • company
    Evaxion A/S

    Clinical‑stage biotech developing AI‑designed immunotherapies.

  • company
    Merck & Co.

    Provider of pembrolizumab (Keytruda) used in combination with EVX-01.

Read at source← All news

StoryEvaxion to present phase‑2 biomarker data for personalized cancer vaccine EVX‑01 at SITC 2026

Also covered by

1 outlet

Related articles

$EVAXMedAI 9/10

Evaxion presents phase 2 cancer vaccine biomarker data at SITC

Evaxion A/S (NASDAQ:EVAX) presented phase 2 trial data for its cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer Annual Meeting. The data showed significant T-cell responses and a strong association between its AI-Immunology platform's predictions and actual immune responses. The trial reported an Objective Response Rate of 75% in advanced melanoma patients.

investing.com
$EVAXMed

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

finanznachrichten.de
$EVAXMedAI 8/10

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

finanznachrichten.de
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de